A large U.S. study found that people assigned female at birth with polyendocrine metabolic ovarian syndrome (PMOS), the condition formerly called polycystic ovary syndrome (PCOS), face substantially higher risks of heart and artery disease than those without the diagnosis.
Study highlights
– Researchers followed 413,450 people with PMOS and compared their insurance claims to more than 2 million without the condition. The average age at the start was about 31.
– Over a 10-year period, roughly 12% of the PMOS group developed heart or artery disease, versus about 4% in the comparison group — an approximate fourfold increase in risk.
– The elevated risk applied across multiple atherosclerotic cardiovascular disease (ASCVD) outcomes and remained significant after adjusting for diabetes, obesity, high blood pressure, and high cholesterol.
– The analysis, published in The Lancet Obstetrics, Gynaecology & Women’s Health, is the largest U.S.-based study to examine this link; much prior research had been conducted outside the United States.
What PMOS is and why the name changed
The condition was renamed earlier in the year to better reflect current understanding. ‘‘Polycystic’’ was misleading: many affected people have follicles — normal structures each containing an egg — rather than abnormal cysts. The new name emphasizes three features:
– Polyendocrine: hormone imbalances
– Metabolic: higher risk of insulin resistance, diabetes, and obesity
– Ovarian: effects on reproductive function
A clearer name aims to improve diagnosis and prompt appropriate follow-up.
How PMOS may raise cardiovascular risk
PMOS is associated with modestly higher androgen levels, insulin resistance, and the metabolic problems that increase cardiovascular risk. The study’s findings suggest that PMOS may identify a population with heightened vascular risk beyond the sum of individual risk factors. Experts note the association does not prove causation, but the magnitude and breadth of the increased risk are notable, especially given the relatively young average age of participants.
Clinical implications and next steps
– Screening and prevention: Clinicians and patients should view a PMOS diagnosis as an opportunity for earlier cardiovascular risk evaluation and prevention rather than a cause for alarm. At a minimum, discussions should cover blood pressure, cholesterol, blood sugar or hemoglobin A1c, weight trends, physical activity, nutrition, tobacco/nicotine use, sleep, and family history of early heart disease.
– Risk calculators: Standard tools that emphasize age may underestimate cardiovascular risk in younger people with PMOS; clinicians may need a lower threshold for further evaluation or intervention.
– Management: Sustainable lifestyle changes that improve insulin sensitivity, blood pressure, and cholesterol can reduce cardiovascular risk, even without major weight loss.
– Research and funding: Authors urged more research on PMOS and other underfunded women’s health conditions (such as menopause, fibroids, and endometriosis) to clarify mechanisms and guide prevention strategies.
Key caveats
The study was observational, so it demonstrates an association but cannot prove PMOS causes cardiovascular events. Not everyone with PMOS will develop heart disease. Nevertheless, the results support earlier monitoring and preventive care for people with PMOS to address modifiable risk factors and potentially reduce long-term cardiovascular harm.
